Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE)

uniQure (NASDAQ:QURE) saw some unusual options trading on Tuesday. Stock traders bought 8,961 call options on the stock. This is an increase of approximately 314% compared to the typical volume of 2,162 call options.

Institutional Trading of uniQure

Large investors have recently modified their holdings of the stock. Invesco Ltd. grew its holdings in shares of uniQure by 453.2% during the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company’s stock worth $10,836,000 after purchasing an additional 502,684 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in uniQure in the fourth quarter valued at about $320,000. Palumbo Wealth Management LLC acquired a new stake in uniQure in the fourth quarter valued at about $437,000. Raymond James Financial Inc. acquired a new stake in uniQure in the fourth quarter valued at about $1,951,000. Finally, Northern Trust Corp boosted its stake in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after buying an additional 1,923 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

QURE opened at $14.96 on Thursday. The firm has a market cap of $819.45 million, a P/E ratio of -3.02 and a beta of 0.10. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The business’s fifty day moving average is $12.64 and its 200-day moving average is $13.04.

uniQure (NASDAQ:QURE) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Sell-side analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, May 24th. Wells Fargo & Company dropped their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. Finally, Cantor Fitzgerald upgraded uniQure to a “strong-buy” rating in a research note on Monday, May 19th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.82.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.